Eli Lilly Acquires Adverum Biotechnologies

Eli Lilly Acquires Verve Therapeutics

July 25, 2025

Biotechnology

Eli Lilly and Company completed the acquisition of Verve Therapeutics, a Boston-based clinical-stage developer of one-time gene-editing therapies for cardiovascular disease. Lilly said the deal will integrate Verve's genetic-medicine programs into its cardiometabolic research to advance potential lifelong cardiovascular risk–reduction treatments.

Eli Lilly Acquires Prevail Therapeutics

December 15, 2020

Biotechnology

Eli Lilly agreed to acquire Prevail Therapeutics for $22.50 per share in cash (approximately $880 million) plus a non-tradable contingent value right (CVR) worth up to $4.00 per share (up to ~$160 million), for total consideration of up to ~$1.04 billion. The deal establishes a gene therapy program at Lilly anchored by Prevail’s AAV9-based neuroscience pipeline; the transaction was structured as a tender offer with expected close in Q1 2021 subject to customary conditions.

Eli Lilly Acquires Versanis Bio

July 14, 2023

Biotechnology

Eli Lilly has entered into a definitive agreement to acquire Versanis Bio, a private clinical-stage biopharmaceutical company developing bimagrumab for cardiometabolic diseases and obesity. The deal could deliver up to $1.925 billion to Versanis shareholders and is intended to combine Versanis’ activin/myostatin biology expertise with Lilly’s incretin portfolio to advance combination treatments for obesity and related cardiometabolic conditions.

Astellas Acquires IVERIC bio for Approximately $5.9 Billion

April 29, 2023

Biotechnology

Astellas Pharma has agreed to acquire 100% of IVERIC bio for $40.00 per share, implying an aggregate equity value of roughly $5.9 billion. The acquisition strengthens Astellas' ophthalmology capabilities and adds Iveric's lead program avacincaptad pegol (ACP) for geographic atrophy secondary to AMD to Astellas' pipeline.

AbbVie Acquires Cerevel Therapeutics

December 6, 2023

Biotechnology

AbbVie Inc. acquired Cerevel Therapeutics for $45.00 per share, valuing Cerevel at approximately $8.7 billion, to bolster AbbVie's neuroscience pipeline. The deal adds Cerevel's clinical-stage assets—including emraclidine, tavapadon, CVL-354 and darigabat—and is intended to expand AbbVie's capabilities and commercial potential in psychiatric and neurological disorders.

Eli Lilly Acquires Morphic

July 8, 2024

Biotechnology

Eli Lilly agreed to acquire Morphic Holding, Inc. for $57 per share (approximately $3.2 billion) to expand its immunology and gastroenterology pipeline with Morphic's oral integrin therapies, including MORF-057. Lilly commenced a tender offer that was completed (with subsequent second-step merger) and the transaction closed in August 2024.